Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AspenBio Pharma Enhances Product Development & Manufacturing Capabilities

Published: Thursday, August 02, 2012
Last Updated: Thursday, August 02, 2012
Bookmark and Share
Company engages diagnostics industry veteran, Lyndal Hesterberg, Ph.D., to spearhead production initiative.

AspenBio Pharma, Inc. announced that Lyndal Hesterberg, Ph.D., has agreed to lead the Company's AppyScore(TM) product development. Dr. Hesterberg brings to AspenBio more than 30 years of experience in the medical diagnostic and biotechnology industry with a diverse background in research, product development and clinical and regulatory successes, including 510(k) submissions. His specific experience includes development of multiplexed IVDMIA "multiple-marker" diagnostic products.

Steve Lundy, President and CEO of AspenBio, commented, "Adding Lyndal to the AspenBio team infuses the company with a proven, experienced medical diagnostic executive who has built a career bringing technologies from bench to bedside. His expertise, particularly in scaling product development for clinical and commercial purposes, will be invaluable as AspenBio prepares to initiate a clinical trial of AppyScore in the third quarter of 2012, targets EU commercialization in the fourth quarter, and seeks FDA clearance and builds towards potential US commercialization in 2013."

Dr. Hesterberg has been a consultant with AspenBio since January 2012 during which time he has played a key role in R&D, product development and clinical and regulatory matters for AppyScore. Prior to joining AspenBio, Dr. Hesterberg served as Chief Technology Officer of Crescendo Bioscience, Inc., a molecular diagnostics laboratory focused on rheumatology. As CTO, Dr. Hesterberg was responsible for the rapid development of multiplexed IVDMIA products.

An entrepreneur as well as a senior operating executive, Dr. Hesterberg founded BaroFold, Inc. in 2003, serving as the company's president and CEO until 2008. In addition to Crescendo and BaroFold, Dr. Hesterberg's career is highlighted by high-ranking directorial and operational positions with SomaLogic, Inc.; Thermo BioStar, Inc.; Amgen, Inc.; and Syngene Products and Research, Inc.

Dr. Hesterberg holds a doctorate in biochemistry from St. Louis University and a bachelors of science, biochemistry from the University of Illinois. He completed his post-doctoral fellow at the Max Planck Institute for Biophysical Chemistry.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!